Levetiracetam is highly effective as add-on treatment in refractory partialonset seizures but there are only limited data supporting its benefit in generalised epilepsies. We have reviewed the clinical records of 25 consecutive adult patients with generalised epilepsies (84% females; mean age 34 (range 16-75) years) prescribed levetiracetam for at least six months. The epilepsy was considered idiopathic in 22 patients (88%)--including 13 with juvenile myoclonic epilepsy--and symptomatic in three. Most patients (68%) reported some improvement in seizure frequency on levetiracetam including 16% who became seizure free. Levetiracetam was generally well tolerated although 11/25 (44%) of patients reported some tiredness, weight change or rash. Levetiracetam was stopped in five patients, four because of side effects and one though lack of efficacy. In four cases, pre-existing antiepileptic medication was withdrawn, leaving levetiracetam as monotherapy. We conclude that levetiracetam is a useful add-on treatment for patients with refractory generalised epilepsies.
Introduction
Levetiracetam (ucb L059) [Keppra] is a secondgeneration antiepileptic drug (AED) shown to be highly effective in the management of partial-onset seizures, and well tolerated compared to other new AEDs. 1 It is an S-enantiomer pyrrolidine derivative, first investigated in the 1980s for its cognitive enhancing and anxiolytic effects. 2 Its antiepileptic properties were noted later, and animal studies have shown a broad spectrum of antiepileptic effect in both partial onset and primarily generalised epilepsies. 3, 4 Since its launch in 2000, levetiracetam has become established as an add-on therapy in the management of partial-onset seizures in adults. There is anecdotal evidence of its effectiveness also in human primarily generalised epilepsies, including those manifesting myoclonic seizures. 5 We have therefore occasionally used levetiracetam outside its current product licence as an add-on AED in patients with resistant generalised epilepsies, and here we report our preliminary experience.
Patients and methods
In 
Results
Twenty-five patients diagnosed with generalised epilepsies were identified from our database who had been prescribed levetiracetam for at least six months before December 2002. One additional patient with unclassified epilepsy had been erroneously categorised as generalised epilepsy and so was excluded. The case notes of all 25 patients [4 males (16%) and 21 females (84%), mean age 34.4 ± 16.6 years (range, 16-75 years)] were available for review. Twenty-two of the 25 patients (88%) had idiopathic generalised epilepsies (IGE). The sub-types of IGE were as follows: unspecified IGE (n = 6), juvenile myoclonic epilepsy (n = 13), epilepsy with generalised tonic-clonic seizures on awakening (n = 1), eyelid myoclonia with absences (n = 1), and peri-oral myoclonia with absences (n = 1). Three patients had symptomatic generalised epilepsies: progressive myoclonus epilepsy Definitions of responses to medication given in text.
(n = 1), generalised epilepsy with severe learning disability (n = 1), and migraine and epilepsy overlap syndrome (migralepsy) (n = 1). The dosing schedule in our patients was generally slower than that recommended by manufacturer. 6 Our usual starting dose was 250 mg daily for one week, increased by 250 mg weekly or two weekly towards a usual maintenance dose of 1000-2000 mg daily. The mean duration of levetiracetam prescription was 14.4 months (range 7-26), and the mean maximum prescribed dose was 1.96 g (range 0.5-3.5 g) daily. The pre-existing AEDs prescribed as monotherapy were sodium valproate n = 14 (56%), lamotrigine n = 4 (16%) and carbamazepine n = 1 (4%). Six patients were prescribed two or more AEDs in various combinations. In four patients (valproate n = 3, carbamazepine n = 1), the pre-existing AED was withdrawn to leave levetiracetam monotherapy.
The clinical responses to levetiracetam are given in Table 1 . Four of the 25 patients (16%) reported becoming seizure free on levetiracetam, with some improvement reported in 17/25 (68%). The seizure response to levetiracetam was similar in those with juvenile myoclonic epilepsy and those with other types of generalised epilepsies. Levetiracetam was stopped in five (20%) patients, four because of adverse side effects and one through lack of efficacy.
Eleven (44%) patients reported significant side effects whilst on levetiracetam. Four reported tiredness, leading one patient to stop the drug. Two reported weight gain and two reported rash, but in each case levetiracetam was continued. Other minor symptoms included bad taste (n = 1), anorexia (n = 1) and dizziness (n = 1).
Discussion
Levetiracetam was effective as add-on treatment in these patients with generalised epilepsies. The large majority (84%) reported some sustained improvement in seizure frequency, and four of the 25 (16%) became seizure free. Furthermore, the retention rate of levetiracetam in these patients was 80% at six months; only one of the four patients who stopped the medication did so though lack of efficacy. The response to levetiracetam was no different in patients with juvenile myoclonic epilepsy than in the remaining patients with other forms of generalised epilepsy.
This study has two important limitations. Firstly, it is a retrospective observational study and therefore reliant upon documentation of clinical features, seizure control and medication side effects in case notes of variable detail and quality. Secondly, the number of patients studied was small, and particularly so given the heterogeneous nature of the generalised epilepsies, the variety of baseline treatments, and the varied dosing schedules of levetiracetam. Nevertheless, these preliminary results do demonstrate that levetiracetam was useful as add-on treatment, even in these patients with resistant generalised epilepsies, with a relatively high rate of seizure freedom and a high rate of medication retention after at least six months of treatment.
There are limited previous data on the use of levetiracetam in generalised epilepsies, used either as add-on or first line treatment. Related pyrrolidone derivatives are known to be effective in primarily generalised epilepsies. 7 However, previous studies suggesting a potential role for levetiracetam in the management of patients with generalised epilepsies have been limited to case reports and uncontrolled and non-randomised data from small series as yet published only in abstract form. 8, 9 However, a larger randomised study using levetiracetam in two oral regimens in a heterogeneous epilepsy population did demonstrate clear improvements in seizure control in both generalised and focal epilepsies. 10 The relatively high retention rate among our patients (80% at six months) is partly attributable to avoidance of unnecessary dose-related side effects through a slow introduction of levetiracetam in these patients compared to the manufacturer's recommendation. 6 The majority of females in the study group was surprising but does not appear to reflect selection bias; indeed, we recognise the potential problems in prescribing a novel medication to women of childbearing potential given the current paucity of safety data on levetiracetam in human pregnancy. In practice, we should advocate withholding levetiracetam from women of childbearing potential unless safer alternatives are either inappropriate or ineffective.
In conclusion, levetiracetam appears to be a useful add-on treatment in patients with resistant generalised epilepsies. Randomised controlled trials are needed to define its role as a second and even as first line monotherapy in generalised epilepsy.
